M
Martin Everett
Researcher at University of Birmingham
Publications - 20
Citations - 1151
Martin Everett is an academic researcher from University of Birmingham. The author has contributed to research in topics: Pseudomonas aeruginosa & Meropenem. The author has an hindex of 8, co-authored 16 publications receiving 1002 citations.
Papers
More filters
Journal ArticleDOI
Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals.
TL;DR: The data indicate that high-level fluoroquinolone resistance in E. coli involves the acquisition of mutations at multiple loci.
Journal ArticleDOI
Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment
John Wain,Nguyen Thi Tuyet Hoa,Nguyen Thuy Chinh,Ha Vinh,Martin Everett,To S. Diep,Nicholas P. J. Day,Tom Solomon,Nicholas J. White,Laura J. V. Piddock,Christopher M. Parry +10 more
TL;DR: It is recommended that short courses of quinolones not be used in patients infected with NARST and that long-course ofloxacin therapy for uncomplicated typhoid should be avoided.
Journal ArticleDOI
Fluoroquinolone resistance in Campylobacter species from man and animals: detection of mutations in topoisomerase genes
TL;DR: Clinical isolates and poultry isolates from Germany, The Netherlands and other regions of the UK collected before 1995 were examined for mutations in the quinolone resistance-determining region of gyrA by single-stranded conformational polymorphism analysis and direct sequencing of a 270 bp fragment of PCR-generated DNA.
Journal ArticleDOI
Discovery of a Novel Metallo-β-Lactamase Inhibitor That Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae.
Martin Everett,Nicolas Sprynski,Alicia Coelho,Jérôme Castandet,Maëlle Bayet,Juliette Bougnon,Clarisse Lozano,David T. Davies,Simon Leiris,Magdalena Zalacain,Ian Morrissey,Sophie Magnet,Kirsty Holden,Peter Warn,Filomena De Luca,Jean Denis Docquier,Marc Lemonnier +16 more
TL;DR: The discovery of a novel MBL inhibitor, ANT431, that can potentiate the activity of meropenem (MEM) against a broad range of MBL-producing CRE and restore its efficacy against an Escherichia coli NDM-1-producing strain in a murine thigh infection model is reported.
Journal ArticleDOI
SAR Studies Leading to the Identification of a Novel Series of Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection Model
Simon Leiris,Alicia Coelho,Jérôme Castandet,Maëlle Bayet,Clarisse Lozano,Juliette Bougnon,Justine Bousquet,Martin Everett,Marc Lemonnier,Nicolas Sprynski,Magdalena Zalacain,Thomas David Pallin,Michael C. Cramp,Neil Jennings,Gilles Raphy,Mark William Jones,Ramesh Pattipati,Battu Shankar,Relangi Sivasubrahmanyam,Ashok Kumar Soodhagani,Ramakrishna R. Juventhala,Narender Pottabathini,Srinivasu Pothukanuri,Manuela Benvenuti,Cecilia Pozzi,Stefano Mangani,Filomena De Luca,Giulia Cerboni,Jean Denis Docquier,David T. Davies +29 more
TL;DR: This work describes the initial exploration of a novel chemical series of metallo-β-lactamase inhibitors, from concept to efficacy, in a survival model using an advanced tool compound (ANT431) in conjunction with meropenem.